CERVIX

NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

The purpose of this study is to compile any good or bad effects of adding triapine to the usual cisplatin chemotherapy and radiation therapy, and compare those results to using cisplatin chemotherapy and radiation therapy alone.

Learn more about the NRG-GY006 trial or call the Protocol Office at 484-628-8193.

RTOG-0724: Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy.

The purpose of this study is to compare any good and/or bad effects of giving additional chemotherapy after the usual treatment of chemotherapy and radiation for cervical cancer. The standard treatment for this type of cervical cancer is cisplatin chemotherapy plus radiation. The study will determine whether adding chemotherapy with carboplatin and paclitaxel (experimental for this type of cervical cancer) to standard radiation and cisplatin chemotherapy improves survival without increasing side effects.

Learn more about the RTOG-0724 trial or call the Protocol Office at 484-628-8193.

GOG-0263: Randomized phase III clinical trial of adjuvant radiation versus chemo-radiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy

The purpose of this study is to determine if weekly chemotherapy with cisplatin and simultaneous radiation therapy increases disease-free time compared to radiation therapy alone.

Learn more about the GOG-0263 trial or call the Protocol Office at 484-628-8193.

ENDOMETRIUM

NRG-GY018: Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

The purpose of this study is to compare the usual treatment of paclitaxel and carboplatin to the combination of paclitaxel, carboplatin, and pembrolizumab.

Learn more about the GOG-0238 trial or call the Protocol Office at 484-628-8193.

FALLOPIAN TUBE

GOG-3035/QPT-ORE-005: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.

This study is being done to see how safe and effective four doses of the experimental drug, oregovomab, is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen consisting of paclitaxel and carboplatin.

Learn more about the GOG-3035/QPT-ORE-005 trial or call the Protocol Office at 484-628-8193.

OVARY

GOG-3035/QPT-ORE-005: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.

This study is being done to see how safe and effective four doses of the experimental drug, oregovomab, is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen consisting of paclitaxel and carboplatin.

Learn more about the GOG-3035/QPT-ORE-005 trial or call the Protocol Office at 484-628-8193.

PERITONEAL

GOG-3035/QPT-ORE-005: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.

This study is being done to see how safe and effective four doses of the experimental drug, oregovomab, is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen consisting of paclitaxel and carboplatin.

Learn more about the GOG-3035/QPT-ORE-005 trial or call the Protocol Office at 484-628-8193.